BTIG raised its price target for Conformis (NASDAQ:CFMS) to $4.50 from $3 after the company arranged $33-million in debt and equity financing from Innovatus Capital Partners and East West Bank. The stock closed at $3.84...

SVB Leerink reduced its price target for Aduro Biotech (NASDAQ:ADRO) to $5 from $8 based on recent ADU-S100 (MIW815) Phase1b dose escalation data presentation at ASCO and re-evaluation of development assumptions in the...

In a new industry report on the future of NASH (nonalcoholic steatohepatitis), Stifel launched coverage of six NASH companies, with three “buy” and three “hold” recommendations.

William Blair downgraded Acer Therapeutics (NASDAQ:ACER) to “market perform” from “outperform” after the company received a complete response letter from the FDA for its lead product, Edsivo (celiprolol).

H.C. Wainwright initiated coverage of Medivir (NASDAQ, Stockholm:MVIR) with a “buy” rating and price target of SEK 54. The stock closed at SEK 22.55 on June 24.

H.C. Wainwright raised its price target for Krystal Biotech (NASDAQ:KRYS) to $56 from $38 after the company posted positive results from its GEM-2 study, a Phase 2 clinical trial of KB103 in patients with recessive...

Ladenburg Thalmann raised its price target for Palatin Technologies (NYSE American:PTN) to $3,75 from $2.75 after the FDA approved Vyleesi as the first as-needed treatment of premenopausal women with acquired...